Global Point-of-Care or Rapid Diagnostics Market Size By Type (Blood Glucose Testing, Infectious Diseases Testing), By Application (Clinics, Hospitals), By Region, And Segment Forecasts, 2023 to 2032

The Global Point-of-Care or Rapid Diagnostics Market was valued at USD 38.1 billion in 2023 and is projected to reach USD 75.4 billion by 2031, expanding at a CAGR of 8.7% during the forecast period (2023–2031). This market is experiencing robust growth due to increasing demand for fast and accurate diagnostic tools, rising prevalence of infectious diseases and chronic conditions, and the growing shift towards decentralized healthcare. The convenience, speed, and cost-efficiency offered by point-of-care diagnostics are transforming disease management in both developed and emerging markets.

Drivers:

1. Growing Prevalence of Chronic and Infectious Diseases:

A significant rise in conditions such as diabetes, cardiovascular diseases, and respiratory infections has escalated the need for immediate diagnostic solutions, boosting market growth.

2. Rising Demand for Decentralized Testing:

The shift from centralized laboratories to bedside, remote, and home-based testing is a major driver. This trend enhances healthcare accessibility and reduces the burden on healthcare infrastructure.

3. Technological Advancements in Diagnostic Devices:

Innovations such as portable molecular testing platforms, biosensors, and smartphone-based diagnostics have improved the accuracy, efficiency, and user-friendliness of rapid diagnostics.

Restraints:

1. Regulatory and Reimbursement Challenges:

Stringent regulatory frameworks and inconsistent reimbursement policies across regions hinder market expansion, especially for novel POC devices.

2. Limited Sensitivity Compared to Lab-based Tests:

Some rapid diagnostic tools may offer lower sensitivity or specificity than traditional methods, leading to concerns over false negatives or positives in critical cases.

Opportunity:

1. Expansion in Emerging Markets:

The increasing penetration of healthcare services in countries like India, Brazil, and South Africa presents lucrative growth opportunities, particularly for portable and affordable diagnostic tools.

2. Integration with Digital Health Platforms:

The convergence of diagnostics with digital tools and telehealth platforms enhances remote monitoring and chronic disease management, opening new revenue streams.

Market by System Type Insights:

In 2023, the Lateral Flow Assays segment dominated the market owing to its cost-effectiveness, ease of use, and widespread application in infectious disease detection. However, the Molecular Diagnostics segment is expected to witness the fastest growth through 2031, driven by the rising need for high-sensitivity testing in decentralized settings.

Market by End-use Insights:

The Hospitals & Clinics segment held the largest share in 2023, benefiting from large-scale testing infrastructure and patient volume. Meanwhile, the Home Care segment is poised for rapid growth, reflecting the surge in self-testing kits for glucose monitoring, COVID-19, and pregnancy diagnostics.

Market by Regional Insights:

North America led the market in 2023, underpinned by advanced healthcare infrastructure, high disease burden, and the presence of leading diagnostics manufacturers. Asia-Pacific is projected to register the highest CAGR during the forecast period, fueled by healthcare reforms, population growth, and increasing awareness of preventive healthcare.

Competitive Scenario:

Key players in the Global Point-of-Care or Rapid Diagnostics Market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, Quidel Corporation, and Thermo Fisher Scientific. These companies are focusing on new product launches, strategic partnerships, and geographic expansion. Noteworthy developments include:

2023: Abbott Laboratories introduced an advanced multiplexed POC molecular testing system capable of detecting multiple pathogens simultaneously.

2024: Roche Diagnostics launched a smartphone-integrated rapid test for cardiovascular risk markers aimed at primary care physicians.

2025: Siemens Healthineers entered a strategic alliance with a digital health company to enhance remote diagnostics for diabetes and hypertension.

Scope of Work – Global Point-of-Care or Rapid Diagnostics Market

Report Metric Details

Market Size (2023) USD 38.1 billion

Projected Market Size (2031) USD 75.4 billion

CAGR (2023–2031) 8.7%